NFKB1 and cancer: In the present study, we report that even a non-cytotoxic dose of docetaxel can induce NF-κB DNA-binding activity in oral cancer cells, thus raising the possibility that cytotoxic doses of docetaxel used in the clinical setting could stimulate, to a greater degree, NF-κB activity in cancer cells.